summary: A new study reveals that Tolcapone, a drug that promotes dopamine, enhances the brain circuits participating in self -control while reducing alcohol intake in people with alcohol abuse (AUD). The drug enhances activity in the lower anterior lid, which is part of the frontal lobe shell, which supports inhibitory control.
Participants who gave Tolcapone have demonstrated the improvement of behavioral performance in the task of inhibiting response and low drinking behavior. These results indicate that the targeting of dopamine in the frontal lobe shell can open a new path to develop more effective AUD treatments.
Main facts
- New goal: Unlike current treatments, Tolcapone treats poor restraint instead of just desire or withdrawal.
- Brain mechanism: The drug enhances dopamine in the frontal lobe crust, which enhances the circles responsible for inhibited control.
- Clinical capabilities: The results support the development of dopamine -based treatments to reduce the abuse of alcohol more effectively.
source: Ambassador
The researchers have identified a promising new strategy for the treatment of alcohol abuse (AUD).
A new study found that the drug that promotes dopamine enhances tolcaponi activity in the frontal lobe shell (PFC) during restraint tasks. A greater activation of the lower anterior witness, part of PFC, has been associated with better behavioral control and reduce alcohol consumption.
The results of this new study in Biological Psychiatry: Knowledge Neuroscience and Nervous Imaging It indicates that medications with a similar mechanism can be used one day to treat AUD.
AUD is a devastating disorder characterized by losing control of alcohol consumption, in which current pharmaceutical treatments are modestly effective. Most approved drug treatments and outside for symptoms of targeted alcohol passion and/or alcohol withdrawal symptoms.
The great author Joseph B. says. Chatt, Department of Psychiatry, Colorado University of Medicine, “We strongly need new drug treatments for AUD. Our study focuses on“ saving ”inherent control, which is the ability of the brain to stop unwanted ideas or procedures, a function that was at risk in AUD.
“Our study indicates that drugs that increase dopamine before frontal are tantamount to follow -up.”
The study included 64 participants with AUD who were randomly set to receive either Tolcapone, which is a drug approved by the FDA in PFC by the suppression of Catechol-OThyLtransferase (COMT), an enzyme that weakens dopamine, or a pillar of position for eight days.
Participants have completed a behavioral control task called the task of “stopping a sign” while undergoing functional nervous imaging (FMRI), during which they had to try to prevent themselves from pressing a button in certain experiences.
This task provokes the activation of the PFC areas that lie behind inhibiting the response. The analysis showed that the tolcapon has increased the stimulation of the cortical areas involved in inhibitory control, and was also evaluated by the oxygen response to the functional magnetic resonance blood.
The main author notes Dro E.
“This association causes the importance of poor control of AUD pathology.”
Editor -in -chief Biological Psychiatry: Knowledge Neuroscience and Nervous Imaging Cameron S. Carter, PhD in Medicine, University of California University, Irvin, that “dopamine is a decisive neurotransmitter involved in fun, motivation, reward, control and decision -making.
The results of this study emphasize the importance of targeting specific brain circuits that control restraint to reduce drinking.
“Future research should continue to investigate the Tolcapone nervous mechanisms and other cortical dopamine modifications to develop more effective AUD treatments.”
On the news of these alcohol and alcohol
author: attacks
source: Ambassador
communication: Eileen Lehi – Embassy
image: The image is attributed to news of neuroscience
The original search: Open access.
“The effects of COMT in a random experience on nervous ties to inhibit the inhibitory treatment between people with alcohol abuseWritten by Joseph B.Chatt and others. Biological Psychiatry: Knowledge Neuroscience and Nervous Imaging
a summary
The effects of COMT in a random experience on nervous ties to inhibit the inhibitory treatment between people with alcohol abuse
background
Multiple organization of inhibitory control is an essential feature of alcohol use disorder (AUD), and is partially mediated by the regulation of catech-or methyl transferraz (COMT) for cortical nervous transport. The Tolcapone, the penetrated COMT inhibitor in the brain, provokes the release of dopamine, and may improve the inhibitory control in AUD.
Blind
Participants who are not residing in the treatment with AUD (N= 64) They were randomly chosen to Tolcapone (calibration to 200 mg TID) or a placebo for 8 days and completed the task of referring to the functional magnetic resonance on school days 1 (before taking the medicine) and 7. The brain areas were identified on day 1 day 1.
The activation of these areas has been tested, and their functional connection with other regions was linked to the changes in drinking during the medication period and with the reaction time, a behavioral indicator of inhibited control.
results
The Tolcapone group showed SS stimulation> SE is larger in the right frontal lobe shell and the bottom anterior flap (IFG). In the Tolcapone group, a larger activation of both fields has been associated with improving inhibitors, and larger IFG activation is associated with low drinking. The increase in connection between IFG and the right front isolation was associated with low drinking, between IFG and the front belt cortex with improved inhibitors.
Conclusions
Tolcapon increased the revitalization of the cortical areas involved in inhibitory control. The links between the increase in IFG and communication, improvement control, and reduce drinking indicate that pharmaceutical interventions that increase the dopamine cortical dopamine may save the unorganized inhibitory control between people with AUD.
2025-08-16 16:26:00
